Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/11602
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yeung, Yvonne | en |
dc.contributor.author | Tebbutt, Niall C | en |
dc.date.accessioned | 2015-05-16T01:13:05Z | |
dc.date.available | 2015-05-16T01:13:05Z | |
dc.date.issued | 2012-10-31 | en |
dc.identifier.citation | Expert Review of Anticancer Therapy 2012; 12(10): 1263-73 | en |
dc.identifier.govdoc | 23113577 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/11602 | en |
dc.description.abstract | Bevacizumab is a humanized monoclonal antibody to VEGF-A, an important therapeutic target through its proangiogenic effects on a variety of tumors. Bevacizumab has demonstrated clinically meaningful benefit in conjunction with chemotherapy for patients with metastatic colorectal cancer as well as other tumor types. Bevacizumab is a well-tolerated therapy with regard to toxicity, in keeping with its biological vascular effect. In this era of personalized medicine, current Phase II and III trials are further defining its role at various stages of metastatic disease and the optimal sequencing with cytotoxic and other targeted agents to achieve further improvements in patient outcome. Translational research for biomarker discovery and validation and further study into mechanisms of resistance are essential for future development and sustained benefit with this class of therapeutic agents. | en |
dc.language.iso | en | en |
dc.subject.other | Angiogenesis Inhibitors.adverse effects.pharmacokinetics.pharmacology.therapeutic use | en |
dc.subject.other | Animals | en |
dc.subject.other | Antibodies, Monoclonal, Humanized.adverse effects.pharmacokinetics.pharmacology.therapeutic use | en |
dc.subject.other | Clinical Trials as Topic | en |
dc.subject.other | Colorectal Neoplasms.blood supply.drug therapy.metabolism | en |
dc.subject.other | Drug Resistance, Neoplasm | en |
dc.subject.other | Humans | en |
dc.subject.other | Randomized Controlled Trials as Topic | en |
dc.subject.other | Tumor Markers, Biological.metabolism | en |
dc.title | Bevacizumab in colorectal cancer: current and future directions. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Expert review of anticancer therapy | en |
dc.identifier.affiliation | Ludwig Institute for Cancer Research, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.doi | 10.1586/era.12.104 | en |
dc.description.pages | 1263-73 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/23113577 | en |
dc.type.austin | Journal Article | en |
local.name.researcher | Tebbutt, Niall C | |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Journal Article | - |
item.fulltext | No Fulltext | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.